NIH Record - National Institutes of Health

Study Answers Question on Blood Sugar Control After Stroke

A doctor shows a female patient her test results on an a tablet screen.
Study results showed that intensive glucose management did not improve functional outcomes at 90 days after stroke compared to standard glucose therapy.

Photo:  Sasha Suzi/Thinkstock

Hyperglycemia, or increased glucose, is common in patients with acute ischemic stroke and is associated with worse outcomes compared to normal glucose levels. Doctors all over the world have debated whether intensive glucose management, which requires the use of IV insulin to bring blood sugar levels down to 80-130 mg/dL, or standard glucose control using insulin shots, which aims to get glucose below 180 mg/dL, lead to better outcomes after stroke. Primary results from the Stroke Hyperglycemia Insulin Network Effort (SHINE) study—a large, multisite clinical study supported by NINDS—provided a clear answer to that question.

The primary results showed that intensive glucose management did not improve functional outcomes at 90 days after stroke compared to standard glucose therapy. In addition, intense glucose therapy increased the risk of very low blood glucose (hypoglycemia) and required a higher level of care such as increased supervision from nursing staff, compared to standard treatment. SHINE findings were presented at the International Stroke Conference on Feb. 6.

The NIH Record

The NIH Record, founded in 1949, is the biweekly newsletter for employees of the National Institutes of Health.

Published 25 times each year, it comes out on payday Fridays.

Editor: Dana Talesnik
Dana.Talesnik@nih.gov

Associate Editor: Patrick Smith
pat.smith@nih.gov

Assistant Editor: Eric Bock
Eric.Bock@nih.gov

Staff Writer: Amber Snyder
Amber.Snyder@nih.gov